TheraRadar
Data updated: May 26, 2026

ZONALON (doxepin hydrochloride)

Immunology Approved 1994-04-01

ZONALON is indicated for the treatment of Pruritus; Atopic Dermatitis; Lichen Simplex Chronicus.

Source: FDA Label • Viatris
1
Indication
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1994-04-01
Routes
TOPICAL
Dosage Forms
CREAM

Companies

Active Ingredient: DOXEPIN HYDROCHLORIDE

ZONALON Approval History

1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 1994 to 2002
Dec 2002 SUPPL
Label · Labeling
Aug 1996 SUPPL
Mfg · Manufacturing (CMC)
Jun 1995 SUPPL
Mfg · Manufacturing (CMC)

What ZONALON Treats

3 indications

ZONALON is approved for 3 conditions since its original approval in 1994. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Pruritus
  • Atopic Dermatitis
  • Lichen Simplex Chronicus
Source: FDA Label

ZONALON Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

What's emerging in ZONALON's indications

See all emerging drugs →

Phase 3 candidates targeting molecules with no FDA-approved drug, in indications ZONALON treats. First-in-class if their pivotal trials read out positive.

Drugs Similar to ZONALON

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

HYDROXYZINE PAMOATE
HYDROXYZINE PAMOATE
2 shared
Novartis
Shared indications:
ADBRY
TRALOKINUMAB
1 shared
LEO PHARMA AS
Shared indications:
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE ACETATE
1 shared
Hikma
Shared indications:
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT02062632 results posted MC13C1 NCI-2014-00253, MC13C1 Ph 2 terminated Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
NCT01156142 results posted NCCTG-N09C6 NCI-2011-02049, CDR0000675520 Ph 3 completed Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ZONALON FDA Label Details

Indications & Usage

FDA Label (PDF)

ZONALON is indicated for the treatment of Pruritus; Atopic Dermatitis; Lichen Simplex Chronicus.

Track ZONALON with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.